Here's What Key Metrics Tell Us About Pfizer (PFE) Q3 Earnings

Core Insights - Pfizer reported revenue of $16.65 billion for the quarter ended September 2025, a decrease of 5.9% year-over-year, with EPS at $0.87 compared to $1.06 in the same quarter last year [1] - The revenue slightly exceeded the Zacks Consensus Estimate of $16.6 billion, resulting in a surprise of +0.3%, while the EPS surprised by +31.82% against a consensus estimate of $0.66 [1] Financial Performance - Pfizer's stock has returned -6.7% over the past month, contrasting with the Zacks S&P 500 composite's +2.1% change, and currently holds a Zacks Rank 4 (Sell) indicating potential underperformance in the near term [3] - Key revenue metrics include: - Oncology - Lorbrena (US): $103 million vs. $117.93 million estimate, +25.6% YoY [4] - Primary Care - Comirnaty (Total International): $282 million vs. $520.81 million estimate, +9.3% YoY [4] - Oncology - Lorbrena (Total International): $165 million vs. $144.21 million estimate, +33.1% YoY [4] - Primary Care - Comirnaty (US): $870 million vs. $621.68 million estimate [4] - Oncology - Ibrance (Worldwide): $1.06 billion vs. $988.24 million estimate, -2.8% YoY [4] - Specialty Care - Xeljanz (Worldwide): $313 million vs. $225.85 million estimate, -2.5% YoY [4] - Specialty Care - Inflectra (Worldwide): $173 million vs. $116.88 million estimate, +37.3% YoY [4] - Oncology - Xtandi (Worldwide): $578 million vs. $591 million estimate, +3% YoY [4] - Oncology - Inlyta (Worldwide): $226 million vs. $187.38 million estimate, -8.5% YoY [4] - Specialty Care (Worldwide): $4.41 billion vs. $4.31 billion estimate, +2.8% YoY [4] - Primary Care - Eliquis (Worldwide): $2.02 billion vs. $1.94 billion estimate, +24.6% YoY [4] - Pfizer CentreOne (Worldwide): $344 million vs. $558.12 million estimate, +20.7% YoY [4]